← All companies
LLY
ELI LILLY & Co · Health Care
8 quarters · 57 figures · latest Q3 FY2026 filed 2026-10-29 →
Compared
6 of 8 · select any line below to add or remove it ·
Revenue
$24.4bn+38.6% Y/YQ3 FY2026
Net income
$6.45bn+15.5% Y/YQ3 FY2026
Earnings per share - diluted
$7.22+16.3% Y/YQ3 FY2026
Gross Margin - As Reported
$20.46bn+40.2% Y/YQ3 FY2026
Operating income
$8.61bn+16.9% Y/YQ3 FY2026
Acquired IPR&D
$4.18bn+537.3% Y/YQ3 FY2026
Reported figures
Click any line for its full history. Each figure links to the filing it was read from.
Income statement
26 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Acquired IPR&Dacquired_iprd | $529m | $584m | $2.78bn | $4.18bn | +537.3% | +50.6% | |
| Cost of salescost_of_sales | $3.37bn | $3.58bn | $3.27bn | $3.93bn | +30.8% | +20.3% | |
| Dividends paid per sharedividends_per_share | $1.50 | $1.73 | $1.73 | $1.73 | +15.3% | +0.0% | |
| Earnings per share - dilutedeps_diluted | $7.39 | $8.26 | $7.94 | $7.22 | +16.3% | −9.1% | |
| Earnings per share – Non-GAAPeps_diluted_non_gaap | $7.54 | $8.55 | $8.38 | $7.48 | +6.6% | −10.7% | |
| Gross Margin - As Reportedgross_margin | $15.92bn | $16.22bn | $19.71bn | $20.46bn | +40.2% | +3.8% | |
| Gross Margin - Non-GAAPgross_margin_non_gaap | $16.04bn | $16.35bn | $19.83bn | $20.59bn | +40.0% | +3.8% | |
| Income tax expenseincome_tax_expense | $1.63bn | $1.45bn | $2.15bn | $1.96bn | +18.5% | −9.2% | |
| Marketing, selling, and administrativemarketing_selling_administrative | $3.13bn | $2.93bn | $3.43bn | $3.13bn | +14.0% | −8.9% | |
| Net incomenet_income | $6.64bn | $7.4bn | $7.1bn | $6.45bn | +15.5% | −9.1% | |
| Net income – Non-GAAPnet_income_non_gaap | $6.77bn | $7.66bn | $7.49bn | $6.68bn | +5.8% | −10.9% | |
| Operating incomeoperating_income | $8.37bn | $8.92bn | $8.98bn | $8.61bn | +16.9% | −4.1% | |
| Research and developmentresearch_and_development | $3.8bn | $3.51bn | $3.82bn | $4.25bn | +22.5% | +11.2% | |
| Revenuetotal_revenue | $19.29bn | $19.8bn | $22.97bn | $24.4bn | +38.6% | +6.2% | |
| Income before income taxesincome_before_income_taxes | — | $8.85bn | $9.25bn | $8.41bn | +16.2% | −9.1% | |
| Other income (expense)other_income_expense | — | −$65m | $269m | −$202m | −53.0% | −175.1% | |
| Asset impairment, restructuring and other special chargesasset_impairment_restructuring_special_charges | — | $279m | $703m | $303m | −17.0% | −56.9% | |
| Acquired IPR&Dacquired_iprd_per_share | — | $0.52 | — | $4.57 | +543.7% | — | |
| Net interest income (expense)net_interest_income_expense | — | — | −$274m | −$316m | −177.2% | −15.3% | |
| Asset impairment, restructuring and other special chargesasset_impairment_restructuring | $84m | — | — | — | −75.6% | — | |
| Weighted-average shares outstanding (thousand) - diluteddiluted_shares | 898,002 | — | — | — | −0.6% | — | |
| Weighted-average shares outstanding (thousand) - diluteddiluted_shares_outstanding | — | — | — | 893,439 | −0.6% | — | |
| Weighted-average shares outstanding (thousand) - diluteddiluted_shares_outstanding_thousands | — | — | 893,671 | — | −0.7% | — | |
| Weighted-average shares outstanding (thousand) - diluteddiluted_shares_thousands | — | 895,918 | — | — | −0.5% | — | |
| Income before income taxesincome_before_taxes | $8.27bn | — | — | — | +64.0% | — | |
| Net other income (expense)net_other_income_expense | — | — | $543m | — | +356.3% | — |
Segments
17 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Mounjaromounjaro_revenue | $7.41bn | $8.66bn | — | $10.72bn | +64.6% | — | |
| Zepboundzepbound_revenue | $4.26bn | $4.16bn | — | $5.35bn | +49.2% | — | |
| Ebglyssebglyss_revenue | — | $145m | — | $202m | +59.1% | — | |
| Jaypircajaypirca_revenue | — | $165m | — | $228m | +59.4% | — | |
| Kisunlakisunla_revenue | — | $124m | — | $193m | +175.7% | — | |
| Omvohomvoh_revenue | — | $80m | — | $114m | +75.4% | — | |
| Inluriyoinluriyo_revenue | — | $35m | — | $73m | — | — | |
| Ebglyssrevenue_ebglyss | — | — | $201m | — | +131.0% | — | |
| Jaypircarevenue_jaypirca | — | — | $192m | — | +56.1% | — | |
| Kisunlarevenue_kisunla | — | — | $167m | — | +240.8% | — | |
| Mounjarorevenue_mounjaro | — | — | $9.94bn | — | +91.2% | — | |
| Omvohrevenue_omvoh | — | — | $102m | — | +36.0% | — | |
| Zepboundrevenue_zepbound | — | — | $4.93bn | — | +45.8% | — | |
| Verzenioverzenio_revenue | $1.6bn | — | — | — | +3.2% | — | |
| Foundayofoundayo_revenue | — | — | — | — | $184m | — | — |
| Foundayorevenue_foundayo | — | — | — | $98m | — | — | — |
| Inluriyorevenue_inluriyo | — | — | — | $75m | — | — | — |
Operating
10 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Key Products revenuekey_products_revenue | — | $13.4bn | $15.7bn | $17.1bn | — | +8.9% | |
| Jardiance sales-based milestonesjardiance_sales_based_milestones | — | — | — | $410m | +105.0% | — | |
| Revenue outside the U.S.outside_us_revenue | — | $7.7bn | — | $9.3bn | — | — | |
| Revenue in the U.S.us_revenue | — | $12.1bn | — | $15.1bn | — | — | |
| Mounjaro revenue outside the U.S.mounjaro_outside_us_revenue | — | — | — | — | $5.7bn | — | — |
| Mounjaro U.S. revenuemounjaro_us_revenue | — | — | — | — | $5bn | — | — |
| Mounjaro revenue outside the U.S.revenue_mounjaro_outside_us | — | — | — | $5.2bn | — | — | — |
| Mounjaro U.S. revenuerevenue_mounjaro_us | — | — | — | $4.8bn | — | — | — |
| Revenue outside the U.S.revenue_outside_us | — | — | — | $8.6bn | — | — | — |
| Revenue in the U.S.revenue_us | — | — | — | $14.4bn | — | — | — |
Margins
4 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Effective tax rate - Reportedeffective_tax_rate | 19.7% | 16.4% | 23.3% | 23.3% | +2.2% | +0.0% | |
| Effective tax rate - Non-GAAPeffective_tax_rate_non_gaap | 19.7% | 16.5% | 22.2% | 24.0% | +35.6% | +8.1% | |
| Gross Margin as a percent of revenue - As Reportedgross_margin_pct | 82.5% | 81.9% | 85.8% | 83.9% | +1.2% | −2.2% | |
| Gross Margin as a percent of revenue - Non-GAAPgross_margin_pct_non_gaap | 83.2% | 82.6% | 86.3% | 84.4% | +1.0% | −2.2% |
Guided vs delivered
What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.
Data from company filings. Not investment advice.